We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Our virtual Center of Excellence in the treatment of Lung Cancer leverages technology to create a collaborative and comprehensive way to improve patient care. This unique center has the key advantages of a real world academic center as well as the features and enhancements that only PracticeUpdate and Elsevier can provide to foster an expert-led team approach that helps you stay ahead.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Rapid sharing of clinical experiences of COVID-19 continues to broaden our collective understanding of this novel virus. This case report outlines fluorodeoxyglucose PET/CT results in a patient with lung cancer undergoing staging who was found to have asymptomatic COVID-19 infection.
The PET/CT images revealed pan-colitis as well as intense inflammatory reaction in the respiratory system despite no symptoms.
– Kolene E. Bailey, MD
This abstract is available on the publisher's site.
A 67-year-old man with no smoking history had a chest radiograph for dyspnea, which identified a right lung nodule. The patient subsequently had a computed tomography (CT) chest which confirmed a spiculated lung nodule suggestive of lung cancer and nothing else. This initiated a diagnostic and staging workup for lung cancer; the time between first CT and positron emission tomography (PET)/CT was 4 weeks. He traveled to Egypt and Jordan after the first CT and 3 weeks before the fluorodeoxyglucose PET/CT. He had no fever or respiratory symptoms. He reported mild gastrointestinal symptoms while traveling, attributed to traveler’s diarrhea. The diarrhea resolved rapidly, 3 weeks before the PET/CT.